Hyalex Orthopaedics Announces FDA 510(k) Clearance of the HYALEX Slalom™ MTP Hemiarthroplasty System

LEXINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Hyalex Orthopaedics today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HYALEX Slalom™ MTP Hemiarthroplasty Implant, a next-generation implant designed around the proprietary Hydrosurf™ materials platform, for the treatment of degenerative conditions affecting the first metatarsophalangeal (MTP) joint, including hallux rigidus.

The Slalom™ MTP Hemiarthroplasty Implant is engineered to restore joint function while preserving bone and soft tissue. Central to the implant is Hyalex’s breakthrough Hydrosurf™ material, a proprietary surface technology designed to closely replicate the biomechanical properties of native cartilage. Together with its advanced implant geometry, the system is designed to reduce pain, maintain range of motion, and provide a reliable alternative to traditional fusion procedures.

The clearance represents a foundational milestone for Hyalex, enabling the company’s first commercial product launch in the United States and marking its entry into the growing foot and ankle reconstruction market.

Sign up for Blog Updates